Investor Presentaiton

TM iTrack™ ADVANCE (1) Based on Nova Eye's sales records • • · • iTrack™ Advance consumable MIGS device is redefining the treatment of glaucoma in its early stages. Canaloplasty offers a stent-free, tissue-preserving surgical treatment for glaucoma using an injector technology Injector technology has enhanced our original iTrack™ which has been used in approx. 130,000 (1) procedures globally. Approved by the FDA on 30 March 2023 and launched in the USA May 2023 nova-eye.com | 10

View entire presentation